402 related articles for article (PubMed ID: 25922181)
21. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues.
Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX
Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885
[TBL] [Abstract][Full Text] [Related]
22. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
23. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
Reddy VG; Bonam SR; Reddy TS; Akunuri R; Naidu VGM; Nayak VL; Bhargava SK; Kumar HMS; Srihari P; Kamal A
Eur J Med Chem; 2018 Jan; 144():595-611. PubMed ID: 29289884
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.
Kamal A; Kumar BA; Suresh P; Juvekar A; Zingde S
Bioorg Med Chem; 2011 May; 19(9):2975-9. PubMed ID: 21489802
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors.
Jiang H; Zhang WJ; Li PH; Wang J; Dong CZ; Zhang K; Chen HX; Du ZY
Bioorg Med Chem Lett; 2018 May; 28(8):1320-1323. PubMed ID: 29545100
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
Karki R; Park C; Jun KY; Jee JG; Lee JH; Thapa P; Kadayat TM; Kwon Y; Lee ES
Eur J Med Chem; 2014 Sep; 84():555-65. PubMed ID: 25062006
[TBL] [Abstract][Full Text] [Related]
27. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and potent cytotoxic activity of novel podophyllotoxin derivatives.
Li WQ; Wang XL; Qian K; Liu YQ; Wang CY; Yang L; Tian J; Morris-Natschke SL; Zhou XW; Lee KH
Bioorg Med Chem; 2013 Apr; 21(8):2363-2369. PubMed ID: 23490151
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.
Brel V; Annereau JP; Vispé S; Kruczynski A; Bailly C; Guilbaud N
Biochem Pharmacol; 2011 Dec; 82(12):1843-52. PubMed ID: 21924246
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.
Zhang R; Wu X; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2011 Dec; 19(23):7023-32. PubMed ID: 22041173
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, crystal structure and antiproliferative activity of Cu(II) nalidixic acid-DACH conjugate: comparative in vitro DNA/RNA binding profile, cleavage activity and molecular docking studies.
Arjmand F; Yousuf I; Hadda Tb; Toupet L
Eur J Med Chem; 2014 Jun; 81():76-88. PubMed ID: 24826817
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis and Cancer Cell Growth Inhibition Evaluation of New Aminoquinone Hybrid Molecules.
Defant A; Mancini I
Molecules; 2019 Jun; 24(12):. PubMed ID: 31197105
[TBL] [Abstract][Full Text] [Related]
34. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
Khalil OM; Gedawy EM; El-Malah AA; Adly ME
Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
[TBL] [Abstract][Full Text] [Related]
35. The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Zhang R; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2009 Jul; 17(13):4575-82. PubMed ID: 19457675
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
[TBL] [Abstract][Full Text] [Related]
38. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, cytotoxicity, HuTopoIIα inhibitory activity and molecular docking studies of pyrazole derivatives as potential anticancer agents.
Alam R; Wahi D; Singh R; Sinha D; Tandon V; Grover A; Rahisuddin
Bioorg Chem; 2016 Dec; 69():77-90. PubMed ID: 27744115
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
